Health Economics›Esophageal squamous cell carcinoma›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Esophageal squamous cell carcinoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	9.3 mo	2	R 573 911 PFS proxy	1
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	6.7 mo	4	R 11 686 PFS proxy	5
Irinotecan monotherapy Variant #01	—	R 2 716	42d	—	6.3 mo	11	R 29 874 PFS proxy	3
Paclitaxel monotherapy Variant #02	—	R 734	28d	—	7.4 mo	6	R 4 406 PFS proxy	4
Camrelizumab monotherapy Variant #01 Partial	—	—	14d	—	8.0 mo	2	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	11.0 mo	2	—	2
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	8.6 mo	2	—	1

7 of 7 regimens shown